Go to the list of all blogs
Allana's Avatar
published in Blogs
Jul 22, 2026
Why Is UiPath (PATH) Stock Down -12.13% Today?

Why Is UiPath (PATH) Stock Down -12.13% Today?

Key Takeaways

  • UiPath shares plunged approximately 12.13% in Wednesday's trading session, dropping from a prior close of $12.04 to $10.58, marking one of the stock's steepest single-day declines of the year.
  • A broad sell-off in AI and technology stocks served as the primary catalyst, with the Nasdaq Composite under pressure and heavyweight AI-linked names sliding in tandem.
  • Persistent concerns about growth deceleration and the disruptive threat that agentic AI poses to UiPath's core robotic process automation (RPA) business continue to weigh heavily on investor sentiment.
  • Elevated short interest — above 30% of the public float — likely amplified the downward move as bearish positioning intensified the selling momentum.
  • Broader market caution around enterprise software spending and a string of recent analyst price-target cuts added to the negative backdrop, leaving the stock vulnerable to sharp corrections.

Opening Summary

PATH, the stock of UiPath Inc. — a New York-based enterprise automation and robotic process automation (RPA) software provider — suffered a severe sell-off on Wednesday, tumbling roughly 12.13% to $10.58 from a prior session close of $12.04. The decline erased weeks of incremental recovery and pushed the shares back toward levels not seen since early July. The rout unfolded alongside a broader downturn in AI-related equities, but UiPath's outsized losses reflected company-specific vulnerabilities that have dogged the stock throughout 2026.

Broad AI and Tech Route Sparks Heavy Selling

The most immediate trigger for Wednesday's plunge was a sector-wide decline in AI and technology stocks. The Nasdaq Composite opened in the red, while the S&P 500 also edged lower. AI-focused names including NOW (ServiceNow), ARM (Arm Holdings), KLAC (KLA Corporation), and MU (Micron Technology) all traded sharply lower at the open. UiPath, however, bore the brunt of the selling, with its decline far outpacing peers — a reflection of the market's diminished tolerance for risk in software names where the growth narrative remains under scrutiny.

Persistent AI Disruption Fears Weigh on Sentiment

Beyond the day's macro-driven pressure, UiPath continues to grapple with an existential question hanging over its business model: can the company thrive in a world where agentic AI threatens to bypass traditional RPA altogether? The rapid proliferation of large language models and autonomous AI agents has raised fears that enterprises may eventually automate workflows without needing an intermediary platform like UiPath. While the company has aggressively repositioned itself — launching agentic AI capabilities, the Maestro orchestration platform, and UiPath for Coding Agents — investors remain unconvinced that these initiatives will translate into sufficiently accelerated revenue growth. First-quarter fiscal 2027 revenue rose a respectable 17% to $418 million, and the company achieved its first GAAP-profitable quarter. Yet annual recurring revenue (ARR) grew at a slower 12% clip, and management's forward guidance implied only modest top-line acceleration, leaving the growth-reacceleration thesis unfulfilled.

Analyst Caution and Heavy Short Interest Amplify the Decline

Wall Street's posture toward PATH has grown increasingly cautious. Over the past two months, UBS, BMO Capital, Morgan Stanley, and DA Davidson have all trimmed their price targets, with several settling in the $12 to $13 range — barely above where the stock traded prior to Wednesday's rout. The consensus rating among 20 analysts sits at Hold. Compounding the bearish technical setup is an unusually high short interest: more than 32% of UiPath's public float was sold short as of mid-June, making the stock highly susceptible to outsized moves on any negative news flow or sector-wide rotation. Wednesday's decline bore the hallmarks of a momentum-driven unwind rather than a reaction to a single discrete catalyst.

Market Context and Trading Activity

Wednesday's plunge came on the heels of already elevated trading volumes. In the prior session, more than 177 million shares changed hands — roughly 235% above the three-month average — signaling heightened investor attention even before the magnitude of today's decline became clear. The stock had recently staged a partial recovery from its 52-week low of $9.20, climbing back above $12, but the breakout lacked conviction. The latest sell-off pushed PATH decisively below its 50-day moving average and toward the lower end of its recent trading range. While the broader application-software peer group also struggled — with APPN (Appian) and PEGA (Pegasystems) each nursing declines earlier in the week — UiPath's losses were disproportionately severe, underscoring the stock's fragility in risk-off conditions.

Trending AI Robots

In volatile market environments like the one affecting UiPath today, traders increasingly turn to data-driven tools to navigate rapidly shifting conditions. Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that have demonstrated the strongest performance under current market dynamics. With hundreds of bots covering thousands of tickers, spanning strategies from swing trading to long-term trend following, only those with proven real-time results earn a place in this featured lineup. Each bot specifies its strategy, timeframe, and tracked symbols, offering traders a transparent view of what is working right now. Explore the Trending AI Robots page to see which automated strategies are navigating today's market with the highest conviction.

What Comes Next for PATH

The immediate focus for PATH shareholders now shifts to the company's next earnings report, expected around September 3, 2026. Analysts are projecting fiscal second-quarter revenue of approximately $397.6 million and earnings per share of $0.15 — flat compared to the year-ago period. The critical metric will be ARR growth: management guided for second-quarter ARR of roughly $1.93 billion, and any shortfall would likely reinforce the bear thesis that UiPath's core subscription engine is losing momentum. Broader macro considerations, including enterprise IT budget scrutiny and the trajectory of interest rates, will also play an outsized role. On the competitive front, investors will monitor whether UiPath's newer agentic AI offerings — including Maestro Case and the recently announced integration for coding agents — begin converting pilot programs into scaled enterprise deployments. Until then, the stock is likely to remain range-bound and reactive to shifts in sector sentiment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: PATH

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


PATH in downward trend: price dove below 50-day moving average on September 15, 2026

PATH moved below its 50-day moving average on September 15, 2026 date and that indicates a change from an upward trend to a downward trend. In 38 of 46 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PATH as a result. In 62 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.

The 10-day moving average for PATH crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 72%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PATH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

The Aroon Indicator for PATH entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PATH's RSI Oscillator exited the oversold zone, 22 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 68 cases where PATH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.

The Moving Average Convergence Divergence (MACD) for PATH just turned positive on October 05, 2026. Looking at past instances where PATH's MACD turned positive, the stock continued to rise in 35 of 44 cases over the following month. The odds of a continued upward trend are 80%.

Following a +8.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where PATH advanced for three days, in 238 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

PATH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.261) is normal, around the industry mean (18.522). P/E Ratio (18.194) is within average values for comparable stocks, (158.311). Projected Growth (PEG Ratio) (0.447) is also within normal values, averaging (3.648). Dividend Yield (0.000) settles around the average of (0.004) among similar stocks. P/S Ratio (4.248) is also within normal values, averaging (104.490).

The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. PATH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PATH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

Notable companies

The most notable companies in this group are Microsoft Corp (NASDAQ:MSFT), Oracle Corp (NYSE:ORCL), Palo Alto Networks Inc (NASDAQ:PANW), Crowdstrike Holdings Inc (NASDAQ:CRWD), Twilio (NYSE:TWLO), Block Inc (NYSE:XYZ), NetApp (NASDAQ:NTAP), Okta (NASDAQ:OKTA), Zscaler (NASDAQ:ZS), MongoDB (NASDAQ:MDB).

Industry description

Computer communications industry develops technology that allows computing devices to exchange data with each other using connections/data links between nodes. Common types of computer network include Cloud (IAN), Internet, Wide (WAN, Local (LAN)/Wireless(WLAN) etc. The industry is an ever-more important part of technology, and is set to become even bigger as the Internet of Things (IoT) rapidly forays into the various aspects of our lives. Cisco Systems, Inc., Palo Alto Networks, Inc. and Arista Networks, Inc., Fortinet, Inc. are some of the major computer communications companies.

Market Cap

The average market capitalization across the Computer Communications Industry is 35.56B. The market cap for tickers in the group ranges from 48.8K to 3.78T. MSFT holds the highest valuation in this group at 3.78T. The lowest valued company is WMHI at 48.8K.

High and low price notable news

The average weekly price growth across all stocks in the Computer Communications Industry was 3%. For the same Industry, the average monthly price growth was -2%, and the average quarterly price growth was 27%. BIRD experienced the highest price growth at 46%, while VERI experienced the biggest fall at -43%.

Volume

The average weekly volume growth across all stocks in the Computer Communications Industry was -1%. For the same stocks of the Industry, the average monthly volume growth was -27% and the average quarterly volume growth was -28%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 47
P/E Growth Rating: 70
Price Growth Rating: 57
SMR Rating: 78
Profit Risk Rating: 91
Seasonality Score: 3 (-100 ... +100)
View a ticker or compare two or three
PATH
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry ComputerCommunications

Industry
N/A
Address
One Vanderbilt Avenue
Phone
+1 844 432-0455
Employees
3981
Web
https://www.uipath.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.